The Regulator and the Regulated Part I: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter
This article was originally published in RPM Report
Executive Summary
FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down for a conversation at the recent FDA/CMS Summit to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment.
You may also be interested in...
Many Drug Approval Delays, Denials Could Be Prevented, FDA Study Shows
Agency reports preventable deficiencies, including failure to select optimal drug doses and suitable study endpoints, account for many drug rejections, approval delays.
If Sponsors Don’t Ask, FDA Can’t Always Deliver: Merck’s Suvorexant Dosing Debacle
Sponsors may need to be more proactive in reaching out to the agency if they want to avoid the kind of dosing confusion currently facing Merck’s insomnia drug suvorexant, FDA indicates.
The Regulator and the Regulated Part II: A Conversation with FDA's Robert Temple and Amgen's Roger Perlmutter
FDA’s dean of drug development Robert Temple and Amgen’s head of research and development Roger Perlmutter sat down to discuss opportunities and challenges for biopharmaceutical developers in the current regulatory environment during The RPM Report’s FDA/CMS Summit for Biopharma Executives. This is part two of that discussion.